Hone Health Home Testosterone Subscription
Hone Health
Hone won by turning testosterone from a clinic errand into a recurring home managed service. Instead of making men book a visit, sit in a waiting room, get labs, then fill a prescription, Hone sold a simpler loop of mail order or local lab testing, telehealth review, doorstep treatment, and repeat blood work every few months. That made a stigmatized category feel private, convenient, and more like a subscription health product than a one off clinic visit.
-
The core difference versus ED telehealth was operational. Ro and Hims could often diagnose from an intake form and ship generics fast, but testosterone is a controlled drug and usually needs ongoing labs, dose changes, and clinician follow up. That extra work made the category harder to copy and improved retention.
-
The money model is concrete. Hone built around a monthly consult membership, then layered on testosterone and related add ons like estrogen control. By the end of 2023, annualized revenue reached about $55M, with ARR later rising to $69.7M in 2024 and $113.5M by September 2025.
-
The broader unlock was regulatory and cultural at the same time. COVID era telemedicine rules made remote prescribing of controlled medicines much easier, while Hone reframed low T from a strip mall clinic purchase into a longevity and energy product marketed across Facebook, Instagram, and TikTok.
This category is moving toward broader hormone and longevity bundles. The same workflow of labs, clinician review, medication tuning, and recurring subscriptions can expand from testosterone into weight loss, thyroid, women’s hormones, and supplements, which gives Hone a path to become a higher LTV multi product telehealth platform instead of a single condition clinic.